Medical & Scientific Affairs.
Deliver greater impact through data-driven, insight-led strategies.
How we help.
We empower Medical & Scientific Affairs teams to deliver greater impact through data-driven, insight-led strategies. Combining deep expertise, pioneering thinking, and AI-enabled analytics, we help you accelerate development, enhance launch readiness, and demonstrate value across the lifecycle – positioning Medical Affairs as a strategic driver of scientific and patient outcomes. We partner with you to:
- Prioritize indications and endpoints, shape registrational pathways, and align scientific narratives to maximize asset potential.
- Design tailored launch strategies built on therapeutic depth, stakeholder mapping, omnichannel engagement, and clear performance metrics.
- Turn evidence into action by applying implementation science, real-world data, health equity strategies, and custom dashboards to track and optimize outcomes.
Some of our experts.
Meet the experts behind the solutions delivering meaningful impact for our clients.
Lori Klein, Partner, Medical and Scientific Affairs Practice Lead
Lori’s expertise spans stakeholder engagement, center-of-excellence profiling, organizational design, strategic medical launches, integrated evidence planning, omnichannel strategy, and digital health platforms including digital therapeutics, AI, and software as a medical device.
Rudiger Papsch, Partner
With 20+ years in healthcare, Rudi partners with pharma, EBPs, government agencies, and nonprofits to develop, launch, and deliver innovative medical treatments and services that benefit patients and health systems.
Brock Staskawicz, Principal
.
Erika Ray, Principal
Erika helps clients develop strategies for pipeline agents, assess commercial opportunities, and address access topics across oncology, vaccine-preventable diseases, immunology, neurology, and rare diseases.
Varun Renjen, Partner, Commercial Practice
Varun is a physician who has been supporting biopharma clients as a strategy consultant for the past 15 years. His areas of focus are commercial strategy, growth strategy, medical affairs, and deals for life science companies worldwide.
Ryan Wyrtzen, Partner
Ryan is a Partner in Putnam’s Value, Pricing & Access Practice, advising biopharma and early-stage companies on pricing and access strategy, new product strategy, and medical affairs strategy at both the portfolio and product level.
Insights & latest.
Access the most up-to-date health and life sciences insights and resources.
-
DownloadsRead more
From Activity to Impact: A Practical Approach to Demonstrating Medical Affairs Value Through Impact Metrics
Discover how Medical Affairs can shift from activity metrics to impact-driven strategies with AI and analytics. Read the full report.
-
Thought LeadershipRead more
MSL Value Beyond Metrics: How Emotion, Storytelling & Strategy Drive True Impact
Insights from the MAPA-MAPS Summit: redefining MSL value through storytelling, emotion, strategy, and smarter measurement.
-
Thought LeadershipRead more
Quantifying MSL Value: A New Lens
Explore how MSLs have evolved into strategic partners in biopharma and why measuring their true value is vital for future success
-
DownloadsRead more
Rethinking Early-Stage Investment Decisions for Novel Antibiotics
Explore a new model for antibiotic investment—driven by AMR, evolving P&R frameworks, and key indicators shaping commercial strategy.
Connect.
Let’s discuss how we can help you.